Dana-Farber Cancer Institute, Inc.

Dana-Farber Cancer Institute, Inc., operating as DFCI, is a nonprofit academic medical research organization affiliated with Harvard Medical School that serves as the prime recipient of federal grants in basic, translational, and clinical cancer research, immunotherapy development, and clinical trial coordination. DFCI operates exclusively in the federal grant space, not federal contracting; across its portfolio the institute received one definitive contract award from the Food and Drug Administration in fiscal 2026 for $1.58 million covering multiomics research on immune checkpoint inhibitor side effects, with ultimate completion in September 2029 and place of performance in Silver Spring, Maryland. The overwhelming majority of DFCI's federal footprint consists of project grants, research training awards, and sub-awards from the National Cancer Institute, the Defense Health Agency, the National Institutes of Health, and other components of the Department of Health and Human Services.

DFCI's concrete federal capability footprint spans hypothesis-driven basic research in cancer biology, translational oncology, immunotherapy engineering, and clinical translational research. The institute conducts mechanism-driven studies of cancer cell cycle regulation, chromatin remodeling, apoptosis pathways, and tumor microenvironment interactions; develops engineered cell therapies including CAR-T constructs for pediatric sarcomas and neuroblastoma; performs clinical trial design and implementation for cancer therapeutics; and operates biomarker discovery and patient-trial matching platforms. Representative recent awards include a $4.2 million Defense Health Agency grant (CFDA 12.420) to conduct Phase 1/2 studies of HALK CAR-T cells for relapsed/refractory high-risk neuroblastoma (completion August 2030), a $2.4 million National Cancer Institute grant (CFDA 93.397) supporting a Specialized Program of Research Excellence (SPORE) in Leukemia spanning three integrated research projects and supporting cores to advance understanding of myeloid leukemia resistance mechanisms (completion July 2031), and a $1.55 million National Cancer Institute grant to develop and deploy ACTIVATE, an open-source AI-driven clinical trial matching tool extending the MatchMiner platform for patient-trial feasibility assessment using natural language processing on electronic health records (completion August 2030, with Mayo Clinic Arizona as a sub-recipient).

Customer concentration heavily favors the National Cancer Institute within the NIH system. The National Cancer Institute awarded 819 grants (74% of the award count tracked across the portfolio), followed by the Defense Health Agency with 110 awards and the National Institute of Allergy and Infectious Diseases with 67 awards. The top five customer agencies (counting NIH as a single entity) account for approximately 74% of all awards. DFCI's award activity has grown from 115 awards in 2022 to 226 in 2024, with 152 in 2025 and 130 in 2026 year-to-date, indicating sustained research funding momentum; 140 awards face ultimate completion within the next twenty-four months, representing significant recompete opportunity across cancer research, immunotherapy, and aging biology domains.

DFCI operates as a prime recipient on 73% of its award portfolio (1,415 awards) and as a sub-recipient on 27% (520 awards), with extensive teaming across the Harvard academic medical ecosystem. The institute frequently serves as a sub-recipient on larger consortium grants anchored at peer institutions including Children's Hospital of Philadelphia (neuroblastoma therapy resistance P01), University of Texas M.D. Anderson Cancer Center (prostate cancer and ovarian cancer clinical trials), Brigham and Women's Hospital (immunotherapy and brain tumor research), and The Broad Institute (sarcoma genomics and rare disease projects). On its prime awards, DFCI engages subcontractors across complementary domains—structural biology, bioinformatics, clinical trial operations, and specialized preclinical modeling—with named subs including Mayo Clinic Arizona, University of Hawaii, and multiple Harvard-affiliated institutions. Service Contract Inventory reporting shows DFCI activity as a named subcontractor on four SCI-reportable contracts across fiscal years 2022–2025, representing approximately 1.4 FTEs in FY2025, a minimal footprint reflecting the institute's primary role as a grant recipient rather than a service contractor.

DFCI's federal grant portfolio spans the National Cancer Institute's Cancer Research Manpower, Cancer Biology Research, Cancer Treatment Research, and Cancer Centers Support Grants programs (CFDA 93.396–93.398, 93.397); the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420); the National Institute on Aging's Aging Research program (CFDA 93.866); the National Heart, Lung, and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837); and specialized programs including the National Institute of General Medical Sciences' Biomedical Research and Research Training program (CFDA 93.859), the National Institute of Diabetes and Digestive and Kidney Diseases' extramural programs, and the NIH Office of the Director's Research Infrastructure and Trans-NIH Research Support programs. The institute is a frequent recipient of R01 project grants, K-series career development awards, and P01 program project grants supporting multi-PI, multi-aim research in leukemia, solid tumors, and basic cancer biology. DFCI also hosts specialized cores and shared resource facilities—including biostatistics, data science, genomics, and pathology cores—that support both its own research and collaborative projects across the Harvard cancer research network.